FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891686688> ?p ?o ?g. }

• W2891686688 abstract "11545 Background: One in two people will be diagnosed with cancer during his/her lifetime. Because we are lacking effective screening tests, most cancers are detected in late stages, when survival rates are very low. Here, we show the development of the first early cancer screening test for multiple cancers using progastrin (PG) as biomarker. The gene coding for PG is a target gene of the Wnt oncogenic pathway that is activated in almost all type of cancers, at the earliest stages of development. We showed that the neutralization of PG by a specific humanized antibody could be used for colorectal cancer treatment. Moreover, as PG is secreted by cancer cells, we can specifically detect it in the blood of persons having a cancer at early stage. Methods: Antibodies directed against PG were produced and selected for target specificity and affinity. ELISA is the most reliable assay to detect biomarker on the blood. Hence, selected antibodies were used to set up an ELISA sandwich to detect PG in the blood of patients with various types of cancers and at various stages. Results: We first set up a prototype ELISA using polyclonal antibodies. We validated our test using 223 blood samples from patients with polyps and colorectal cancers at various stages for which we observed an increased levels of PG. Then, we showed the presence of PG in the blood of 212 patients with other types of cancer, including liver, pancreatic and breast cancers, confirming that PG could be used as a biomarker for multiple types of cancers. Next, we set up our industrial ELISA using polyclonal and monoclonal antibodies called DECODE Lab and tested 245 new blood samples from patients with various types of cancer including early stages. Strikingly, using our test we were able to detect breast (AUC = 0.9638; sensitivity 70%), colorectal (AUC = 0.9635; sensitivity 73%), melanoma (AUC = 0.9882; sensitivity 87%) and cervix utery (AUC = 0.9827; sensitivity 84%) all stages combined with a high specificity of 97.5%. Finally, for early stage patients with melanoma and breast cancer, we had a sensitivity of 68% and 81% respectively. Conclusions: Taken together, the results presented here show that PG is a reliable biomarker for early cancer screening. The ELISA test that we developed is very efficient and now available for the clinic." @default.
• W2891686688 created "2018-09-27" @default.
• W2891686688 creator A5002877692 @default.
• W2891686688 creator A5014415808 @default.
• W2891686688 creator A5019940028 @default.
• W2891686688 creator A5031564329 @default.
• W2891686688 creator A5039119608 @default.
• W2891686688 creator A5039535296 @default.
• W2891686688 creator A5042031589 @default.
• W2891686688 creator A5045755661 @default.
• W2891686688 creator A5060046059 @default.
• W2891686688 date "2017-05-20" @default.
• W2891686688 modified "2023-10-17" @default.
• W2891686688 title "Progastrin: A new specific early cancer screening biomarker." @default.
• W2891686688 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11545" @default.
• W2891686688 hasPublicationYear "2017" @default.
• W2891686688 type Work @default.
• W2891686688 sameAs 2891686688 @default.
• W2891686688 citedByCount "0" @default.
• W2891686688 crossrefType "journal-article" @default.
• W2891686688 hasAuthorship W2891686688A5002877692 @default.
• W2891686688 hasAuthorship W2891686688A5014415808 @default.
• W2891686688 hasAuthorship W2891686688A5019940028 @default.
• W2891686688 hasAuthorship W2891686688A5031564329 @default.
• W2891686688 hasAuthorship W2891686688A5039119608 @default.
• W2891686688 hasAuthorship W2891686688A5039535296 @default.
• W2891686688 hasAuthorship W2891686688A5042031589 @default.
• W2891686688 hasAuthorship W2891686688A5045755661 @default.
• W2891686688 hasAuthorship W2891686688A5060046059 @default.
• W2891686688 hasConcept C121608353 @default.
• W2891686688 hasConcept C126322002 @default.
• W2891686688 hasConcept C143998085 @default.
• W2891686688 hasConcept C2781197716 @default.
• W2891686688 hasConcept C54355233 @default.
• W2891686688 hasConcept C71924100 @default.
• W2891686688 hasConcept C86803240 @default.
• W2891686688 hasConceptScore W2891686688C121608353 @default.
• W2891686688 hasConceptScore W2891686688C126322002 @default.
• W2891686688 hasConceptScore W2891686688C143998085 @default.
• W2891686688 hasConceptScore W2891686688C2781197716 @default.
• W2891686688 hasConceptScore W2891686688C54355233 @default.
• W2891686688 hasConceptScore W2891686688C71924100 @default.
• W2891686688 hasConceptScore W2891686688C86803240 @default.
• W2891686688 hasLocation W28916866881 @default.
• W2891686688 hasOpenAccess W2891686688 @default.
• W2891686688 hasPrimaryLocation W28916866881 @default.
• W2891686688 hasRelatedWork W1492603006 @default.
• W2891686688 hasRelatedWork W1523964304 @default.
• W2891686688 hasRelatedWork W1989211748 @default.
• W2891686688 hasRelatedWork W1992759183 @default.
• W2891686688 hasRelatedWork W2013040910 @default.
• W2891686688 hasRelatedWork W2014417067 @default.
• W2891686688 hasRelatedWork W2052289427 @default.
• W2891686688 hasRelatedWork W2081909691 @default.
• W2891686688 hasRelatedWork W2118656195 @default.
• W2891686688 hasRelatedWork W2163085131 @default.
• W2891686688 hasRelatedWork W2165288826 @default.
• W2891686688 hasRelatedWork W2261070115 @default.
• W2891686688 hasRelatedWork W2308896852 @default.
• W2891686688 hasRelatedWork W2589803447 @default.
• W2891686688 hasRelatedWork W2754654527 @default.
• W2891686688 hasRelatedWork W2901035387 @default.
• W2891686688 hasRelatedWork W2991773883 @default.
• W2891686688 hasRelatedWork W3046318933 @default.
• W2891686688 hasRelatedWork W65319274 @default.
• W2891686688 hasRelatedWork W168366594 @default.
• W2891686688 isParatext "false" @default.
• W2891686688 isRetracted "false" @default.
• W2891686688 magId "2891686688" @default.
• W2891686688 workType "article" @default.